SPINK2 Small Molecule Inhibitor for Leukemic Stem Cell Eradication

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatment strategies for Acute Myeloid Leukemia (AML) are suboptimal due to high relapse rates attributed to residual leukemic stem cells (LSCs), and there is a lack of effective biomarkers for identifying high-risk patients and predicting treatment outcomes.

Innovation Solution

A method for identifying high-risk AML patients based on SPINK2 protein expression quantified by immunohistochemical (IHC) scores, and a small molecule inhibitor (SMI) that selectively targets SPINK2 in leukemic stem cells to inhibit proliferation and induce death in these cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatment strategies are used for AML, then standard care is provided, but high relapse rates occur due to residual leukemic stem cells

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidrelapse risk

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent extracts and targets SPINK2 specifically as a marker and therapeutic target in leukemic stem cells. By identifying and eliminating this specific protein function, the treatment aims to remove the harmful residual LSC population that causes relapse, rather than treating all leukemia cells uniformly.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent applies local quality by targeting SPINK2 expression specifically in leukemic stem cells rather than treating all AML cells alike. The small molecule inhibitor is designed to selectively inhibit SPINK2 function in LSCs, creating a differentiated treatment approach that addresses the specific vulnerability of this cell population.

Inventive Principle:

Principle #3Local quality

2Reliability

If SPINK2 is targeted with a small molecule inhibitor, then leukemic stem cell proliferation is inhibited and death is induced, but the complexity of treatment selection increases

Engineering Contradiction:

Improveleukemic stem cell eradicationVSAvoidtreatment identification process

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent performs preliminary action by using immunohistochemical staining to pre-identify patients with high SPINK2 expression before initiating treatment. This stratification step separates high-risk patients who would benefit from SPINK2 inhibition from those who would not, enabling personalized treatment selection based on predefined biomarker criteria.

Inventive Principle:

Principle #10Preliminary action

3Measurement precision

If SPINK2 protein expression is quantified using immunohistochemical scores, then high-risk patients are identified, but the measurement and scoring process becomes complex

Engineering Contradiction:

ImproveSPINK2 expression quantificationVSAvoidIHC scoring system

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent segments the complex IHC assessment into discrete, quantifiable components: staining intensity (0-4 scale) and percentage of positive cells (0-100%). This segmentation transforms the qualitative visual assessment into quantitative data that can be objectively scored and used for patient stratification, making the complex measurement process more standardized and reproducible.

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method effectively identifies high-risk AML patients and the SMI treatment potentially eradicates leukemic stem cells, improving treatment outcomes and reducing premature deaths.

Implementation Method 1

a small molecule inhibitor (SMI) that selectively targets SPINK2 in leukemic stem cells to inhibit proliferation and induce death in these cells

Methodology Applied

Scientific EffectMolecular inhibition:

Implementation Method 2

SPINK2 protein expression quantified by immunohistochemical (IHC) scores

Methodology Applied

Scientific EffectImmunohistochemistry:

Data Source

PatentUS20250138013A1Small molecule inhibitor targeting a leukemic stem cell associated gene for high-risk AML patients

Publication Date: 2025.05.01 THE CHINESE UNIVERSITY OF HONG KONG

AI summary

Disclosed a method of identifying high-risk Acute Myeloid Leukemia patients based upon the expression of a leukemic stem-cell (LSC) associated gene known as Serine Protease Inhibitor Kazal type 2 (SPINK2), the method including: (i) Immunohistochemistry (IHC)-based detection of SPINK2 protein expression, (ii) quantification of SPINK2 expression using a scoring system (range 0-16), whereby high SPINK2 is defined as a score>3 and (iii) utilization of the score to classify patients as high-risk (score>3) or low risk (score 0-3). Additionally, disclosed is a method of treating AML using a small molecule inhibitor (SMI) that selectively targets a domain of SPINK2 protein in leukemic cells highly expressing SPINK2; wherein the SMI reduces SPINK2 protein expression, alters SPINK2 target gene mRNA expression, inhibits SPINK2 function and consequently LSC proliferation/survival. A method of identifying potential candidates for SPINK2-SMI therapy to enhance treatment outcomes, whereby potential candidates refer to patients with high SPINK2 expression, is also disclosed.